Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Future You Cambridge is a company that sells clinically proven health supplements directly to consumers. Since its launch in 2016, it has sold products to over 100,000 customers. The company's Lactolycopene product received a patent in December 2017 and its Fertility+ product was also covered by the European Journal of Nutrition in a clinical paper and was shown to have resulted in a 40% increase in male fertility. The company's offerings now stand at 24 products, including the popular CBD product and its first product for pets, Curcupet-K9. Additionally, the company won the 2018 Cambridge Service Excellence and Independent High Growth Business of the Year Awards and has 5-star ratings on Trustpilot. They will use the investment to scale up direct advertising campaigns, expand its product range by more than 10 new products, and invest in their website to make it more intuitive.
days to go:
Expired
investment:
£655,011
By combining fitness with fashion, art and design, BLOK has become a major competitor of boutique class-based gyms within London. BLOK has appeared on Britain's Next Top Model, as well as working with global stars including Anthony Joshua and Jordan Dunn.
days to go:
Expired
investment:
£891,790
Pull'd is a food-to-go operator that is focused around selling slow cooked meats in London. They serve a range of different meats on a range of different bases.
days to go:
Expired
investment:
£30,450
Noveltea is a premium alcoholic tea brand launched in Fenwick in April 2017. The company's products are vegan, gluten-free and low in sugar, and manufactured in minimalistic & up-cyclable lifestyle packaging. Thanks to its low-Alcohol by volume (ABV) portfolio, the brand has sold 350,000 bottles since its launch in 2017. The company experienced more than £100,000 worth of sales in April 2020 despite COVID-19 due to smart e-commerce channel utilisation. In 2020, the size of the global alcoholic drinks market is $1.587 trillion and is forecasted to grow by 3.5% (CAGR) over the next three years. The brand aims to become a major contender in this segment and grow its business. The company use the investment to focus on its core markets in the UK, Germany, and China, and enter the USA by 2020.
days to go:
Expired
investment:
£558,845
An innovative and flourishing brewery, with music as its main source of inspiration. Signature Brew has won multiple awards for their beers, including the SIBA for Brewery Business of the Year 2018. The company is passionate abut serving brews alongside bands; their collaborations include Foo Fighters, Frank Turner, Mastodon and alt-J.
Signature Brew's core beers are enjoyed nationwide, such as Studio Pilsner and Roadie. Their products are sold in bars, pubs and supermarkets, as well as at venues and festivals. Over the past 3 years, the company has seen YoY growth of 78%, with revenues of £1.13m in the last 12 months.
Signature Brew is currently producing over 1m pints per year and is now seeking investment to increase capacity. The company intends to move its services to a nearly site in East London and develop a new brew house. This will result in capacity increasing by three-fold. In addition, Signature Brew intends to open two more taprooms to host events and showcase their beers.
days to go:
Expired
investment:
£567,030
SteakOut Meat House is a brand that currently has 8 franchised restaurants, and are expanding rapidly across the country. They are also the most recognised halal steak restaurant in the UK.
days to go:
Expired
investment:
£129,410
Erpingham House is the UK’s largest vegan restaurant whose aim is to make plant-based dining into the mainstream and provide delicious, healthy food and drinks to people. The company has earned nationwide recognition and, it has been listed in The Times top 20 vegetarian restaurants. It has also been featured in The Guardian and on channel 4’s “what Britain bought.” EH has served over 12,000 customers in its first year and, it has risen to over 20,000 followers on Instagram. The funds will be used to expand the brand & open a second site in Brighton.
days to go:
Expired
investment:
£192,280
